Research Article
Cytogenetic as an Important Tool for Diagnosis and Prognosis for Patients with Hypocellular Primary Myelodysplastic Syndrome
Table 2
Correlation of karyotypes and the clinical features in patients with hypocellular primary MDS.
| Patient’s variables |
Number of patients/frequency (%) | Karyotypes (%) | value | Evolution from MDS to AML | value | Mortality | value | Normal | Abnormal |
| Age | | | | < 0,05 | | NS* | | < 0,05 | ≤18 years (pediatric patients) | 39 (37%) | 12 (31%) | 27 (69%) | | 39/9 | | 39/12 | | >18 years (adult patients) | 66 (63%) | 35 (53%) | 31 (47%) | | 66/10 | | 66/36 | | Sex | | | | NS* | | NS* | | NS* | Male | 56 (53%) | 20 (36%) | 36 (64%) | | 56/11 | | 56/26 | | Female | 49 (47%) | 27 (55%) | 22 (45%) | | 49/8 | | 49/22 | | MDS subtypes/% of bone marrow blasts | | | | < 0,0002 | | < 0,0001 | | < 0,0005 | Initial stage RA/<5% | 81 (77%) | 47 (58%) | 34 (42%) | | 81/2 | | 81/27 | | Advantage stages RAEB and RAEB-t ≥5% | 24 (23%) | 0 | 24 (100%) | | 24/17 | | 24/21 | | IPSS | | | | < 0,0001 | | < 0,0001 | | < 0,001 | Low | 0 (0%) | — | — | | — | | — | | Int-1 | 78 (74%) | 47 (60%) | 31 (40%) | | 78/0 | | 78/25 | | Int-2 | 17 (16%) | 0 (0%) | 17 (100%) | | 17/9 | | 17/13 | | High | 10 (10%) | 0 (0%) | 10 (100%) | | 10/10 | | 10/10 | |
|
|
*No significance.
|